About this document

Lutetium-177 PSMA Therapy for Prostate Cancer by Louis Lee is a document available to read on EtoBox.

Lutetium-177 PSMA therapy (Pluvicto) is a targeted radiation treatment for advanced metastatic prostate cancer, approved by the FDA in March 2022, which significantly improves survival rates and quality of life. It works by attaching to the PSMA molecule on cancer cells, delivering radiation that damages their DNA. UChicago Medicine is a leader in this therapy, offering extensive experience and participation in clinical trials to enhance treatment options for patients.

Author

Louis Lee

Language

EN